A Phase 2b, Open-Label, Single-Arm Study Of Selinexor (KPT-330) Plus Low-Dose Dexamethasone In Patients With Multiple Myeloma Refractory To Bortezomib, Lenalidomide, Carfilzomib And Pomalidomide

ID Number 15-1782

Principal Investigator(s)
Sundar Jagannath

Department(s) or Division(s)
Hematology and Medical Oncology


The purpose of this research study is to see if study drug selinexor (KPT-330) has any effects against your cancer.  Selinexor (KPT-330) is considered investigational, which means it has not been approved by the U.S. Food and Drug Administration (FDA), Health Canada, the European Medicines Agency (EMA) or any other national competent authority.

Contact Information
Lisa La

Recruiting Patients: Yes